Related references
Note: Only part of the references are listed.Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer
Bo Gong et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations
Shinnosuke Ikemura et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations
Sheng-Kai Liang et al.
LUNG CANCER (2019)
Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype
Daehwan Kim et al.
NATURE BIOTECHNOLOGY (2019)
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Hirokazu Taniguchi et al.
NATURE COMMUNICATIONS (2019)
Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance
Koutaroh Okada et al.
EBIOMEDICINE (2019)
A secondary RET mutation in the activation loop conferring resistance to vandetanib
Takashi Nakaoku et al.
NATURE COMMUNICATIONS (2018)
Non-small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report
Jing Huang et al.
THORACIC CANCER (2018)
EGFR L747P mutation in one lung adenocarcinoma patient responded to afatinib treatment: a case report
Tong Zhou et al.
JOURNAL OF THORACIC DISEASE (2018)
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
Ken Uchibori et al.
NATURE COMMUNICATIONS (2017)
The Effect of Conformational Flexibility on Binding Free Energy Estimation between Kinases and Their Inhibitors
Mitsugu Araki et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2016)
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
Yong Jia et al.
NATURE (2016)
Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors
Yoshitaka Seki et al.
ONCOLOGIST (2016)
Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report
Yu-Ting Wang et al.
JOURNAL OF THORACIC DISEASE (2016)
The Ensembl Variant Effect Predictor
William McLaren et al.
GENOME BIOLOGY (2016)
Uncommon EGFR Exon 19 Mutations Confer Gefitinib Resistance in Advanced Lung Adenocarcinoma
Simona Coco et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
James C-H Yang et al.
LANCET ONCOLOGY (2015)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih-Hsin Yang et al.
LANCET ONCOLOGY (2015)
Trimmomatic: a flexible trimmer for Illumina sequence data
Anthony M. Bolger et al.
BIOINFORMATICS (2014)
Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Ryohei Katayama et al.
CLINICAL CANCER RESEARCH (2014)
A cautionary lesson on the use of targeted methods for EGFR mutation analysis: a case report
K. Walsh et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
Effectiveness of Gefitinib against Non-Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
Satoshi Watanabe et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
Yelena Y. Janjigian et al.
CANCER DISCOVERY (2014)
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Kristian Cibulskis et al.
NATURE BIOTECHNOLOGY (2013)
EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
Mai He et al.
CLINICAL CANCER RESEARCH (2012)
A Novel EGFR Mutation in Exon 19 Showed Stable Disease After TKI Treatment
Anthonie J. van der Wekken et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
King Pan Ng et al.
NATURE MEDICINE (2012)
Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations
Tommaso De Pas et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
A framework for variation discovery and genotyping using next-generation DNA sequencing data
Mark A. DePristo et al.
NATURE GENETICS (2011)
Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib
Vince D. Cataldo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
Aaron McKenna et al.
GENOME RESEARCH (2010)
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
William Pao et al.
NATURE REVIEWS CANCER (2010)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
Massively parallel computation of absolute binding free energy with well-equilibrated states
Hideaki Fujitani et al.
PHYSICAL REVIEW E (2009)
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Xuewu Zhang et al.
CELL (2006)
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
W Pao et al.
PLOS MEDICINE (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
S Kobayashi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)